Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) price on Friday, June 13, fall -0.19% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $62.90.
A look at the stock’s price movement, the close in the last trading session was $63.02. Turning to its 52-week performance, $69.89 and $39.46 were the 52-week high and 52-week low respectively. Overall, RYTM moved 9.81% over the past month.
Rhythm Pharmaceuticals Inc’s market cap currently stands at around $4.00 billion, with investors looking forward to this quarter’s earnings report slated for in July.
5 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 5 recommend RYTM as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
RYTM’s current price about -0.68% and 2.41% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 49.70, while 7-day volatility ratio is 2.24% and 2.73% in the 30-day chart. Further, Rhythm Pharmaceuticals Inc (RYTM) has a beta value of 2.30, and an average true range (ATR) of 2.72. Analysts have given the company’s stock an average 52-week price target of $78, forecast between a low of $70 and high of $80. Looking at the price targets, the low is -11.29% off current price level while to achieve the yearly target high, price needs to move -27.19%. Nonetheless, investors will most likely welcome a -24.01% jump to $78 which is the analysts’ median price.
If we refocus on Rhythm Pharmaceuticals Inc (NASDAQ:RYTM), historical trading data shows that trading volumes averaged 713.05K over the past 3 months. The company’s latest data on shares outstanding shows there are 63.49 million shares.
The 8.48% of Rhythm Pharmaceuticals Inc’s shares are in the hands of company insiders while institutional holders own 95.60% of the company’s shares. Current price change has pushed the stock 12.36% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the RYTM stock continues to rise going into the next quarter.
